AU Patent

AU2011205024B2 — Multiple PPI dosage form

Assigned to Takeda Pharmaceutical Co Ltd · Expires 2012-09-06 · 14y expired

What this patent protects

MUL TIPLE PPI D OSA GE FORM Abstract 5 Herein provided are dosage forms (variously referred to as "formulations") comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma l…

USPTO Abstract

MUL TIPLE PPI D OSA GE FORM Abstract 5 Herein provided are dosage forms (variously referred to as "formulations") comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.

Drugs covered by this patent

Patent Metadata

Patent number
AU2011205024B2
Jurisdiction
AU
Classification
—
Expires
2012-09-06
Drug substance claim
No
Drug product claim
No
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.